Core Viewpoint - CICC maintains a "outperform" rating for Yuan Da Pharmaceutical (00512) and raises the target price by 33.3% to HKD 7.2 [1] Financial Performance - The company reported a net profit of HKD 2.47 billion, a year-on-year increase of 31.3%, exceeding CICC's expectations [1] - The growth was primarily driven by higher-than-expected nuclear medicine volume and gains from Telix equity investments [1] Earnings Forecast - CICC maintains the earnings per share (EPS) forecast for this year at HKD 0.6 and introduces a new EPS forecast of HKD 0.63 for 2026 [1] Business Segments - The nuclear medicine segment is experiencing rapid growth, with the RDC pipeline expected to start generating revenue in 2025 [1] - The traditional business segment remains stable, with attention on the clinical results of STC3141 for sepsis, with preliminary results expected in the first half of this year [1]
中金：维持远大医药(00512)“跑赢行业”评级 上调目标价至7.2港元